Invivoscribe is an industry pioneer with over 20 years of experience in developing and manufacturing diagnostic products and reagents. They are dedicated to improving lives through precision diagnostics. Invivoscribe offers a wide range of products and services that are designed to enhance patient care.

Their product portfolio includes next-generation sequencing (NGS) assays, companion diagnostics (CDx), controls, reagents, and software solutions. These products are used for the detection of various genetic mutations and rearrangements associated with hematological cancers such as lymphoma, myeloma, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). In addition to their products, Invivoscribe also provides comprehensive clinical lab services through their Laboratory for Personalized Molecular Medicine (LabPMM).

They offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care. With their expertise, innovative technologies, and commitment to quality, Invivoscribe continues to lead the way in precision diagnostics, providing healthcare professionals with reliable tools to make informed treatment decisions and improve patient outcomes